To test this hypothesis, we conducted ATAC-seq and phospho-Smad3 chromatin immunoprecipitation sequencing (ChIP-seq) in resistant nMRTF BCC cells treated with AP-1 inhibitor. This evidence concerns the gene SMAD3 and skin basal cell carcinoma.